March 26 (Reuters) - The following is a list of the top 20
pharmaceutical companies, ranked by global prescription drug
sales for the 12 months through September 2009, according to
pharmaceutical market research company IMS Health Inc.
The chart shows sales -- in billions of U.S. dollars -- and percent change over the period. The data does not include the results from mega acquisitions by Pfizer and Merck , as their deals for Wyeth and Schering-Plough, respectively, were completed in the fourth quarter.
A year after a wave of mega-mergers shook up the pharmaceutical industry, the remaining big drugmakers most often mentioned as takeout or merger candidates appear set to go it alone as they edge toward their patent cliffs.
Company Sales pct change
1) Pfizer $41.7 (0.8)
2) Novartis $36.7 7.0
3) Sanofi
Aventis $35.1 3.3
4) GlaxoSmithKline $34.3 (3.4)
5) AstraZeneca $33.2 7.8
6) Roche $31.3 8.6
7) Johnson & Johnson $26.9 (6.6)
8) Merck & Co $25.0 (4.1)
9) Eli Lilly $19.6 8.3
10) Abbott $19.4 5.5
11) Teva $15.7 12.3
12) Bayer $15.4 3.9
13) Wyeth $14.8 (2.3)
14) Amgen $14.8 (3.1)
15) Boehringer $14.6 10.4
16) Takeda $14.4 2.1
17) Bristol
Myers $14.2 5.8
18) Schering
Plough $13.1 4.3
19) Daiichi Sankyo $8.5 3.1
20) Novo Nordisk $8.2 11.6
(Source: IMS Health) Keywords: PHARMACEUTICAL/MERGERS (lewis.krauskopf@thomsonreuters.com; + 646 223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The chart shows sales -- in billions of U.S. dollars -- and percent change over the period. The data does not include the results from mega acquisitions by Pfizer and Merck , as their deals for Wyeth and Schering-Plough, respectively, were completed in the fourth quarter.
A year after a wave of mega-mergers shook up the pharmaceutical industry, the remaining big drugmakers most often mentioned as takeout or merger candidates appear set to go it alone as they edge toward their patent cliffs.
Company Sales pct change
1) Pfizer $41.7 (0.8)
2) Novartis $36.7 7.0
3) Sanofi
Aventis $35.1 3.3
4) GlaxoSmithKline $34.3 (3.4)
5) AstraZeneca $33.2 7.8
6) Roche $31.3 8.6
7) Johnson & Johnson $26.9 (6.6)
8) Merck & Co $25.0 (4.1)
9) Eli Lilly $19.6 8.3
10) Abbott $19.4 5.5
11) Teva $15.7 12.3
12) Bayer $15.4 3.9
13) Wyeth $14.8 (2.3)
14) Amgen $14.8 (3.1)
15) Boehringer $14.6 10.4
16) Takeda $14.4 2.1
17) Bristol
Myers $14.2 5.8
18) Schering
Plough $13.1 4.3
19) Daiichi Sankyo $8.5 3.1
20) Novo Nordisk $8.2 11.6
(Source: IMS Health) Keywords: PHARMACEUTICAL/MERGERS (lewis.krauskopf@thomsonreuters.com; + 646 223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
